Abstract
From what has been sald so far it should be apparent that it is not really possible to draw clear cut qualitative distinctions, either in clinical or pathological terms, between the effects of so-called normal aging and those of the common neurodegenerative diseases of later life (i.e. AD, PD). Pathological diagnoses of AD and PD are made on the basis of the amount, rather than the type, and distribution of damage imposed upon the brain. In clinical terms this degree of damage may be represented by a subthreshold scoring on rating systems designed to test powers of memory or reasoning, or motor function. Such observations imply that aging and neurodegeneration might exist on a sliding scale of change the one inevitably leading, with time, into the other, with a certain and perhaps rather arbitrary “cut off point” separating the two.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hubbard BM, Anderson JM. Age, senile dementia and ventricular enlargement. J Neurol Neurosurg Psychiatry 1981; 14: 631–635.
George AE, de Leon MJ, Ferris SH et al. Parenchymal CT correlates of senile dementia (Alzheimer’s disease): Loss of gray-white matter discriminability. Am J Neuroradiol 1981; 2: 205–213.
Huckman MS, Fox J, Topel J. The validity of criteria for the evaluation of cerebral atrophy by computed tomography. Radiology 1975; 116: 85–92.
Koller WC, Glatt SL, Fox JH et al. Cerebellar atrophy: relationship to aging and cerebral atrophy. Neurology 1981; 31: 1486–1488.
Drayer BP, Heyman A, Wilkinson W et al. Early onset Alzheimer’s disease: An analysis of CT findings. Ann Neurol 1985; 17: 407–410.
Gado M, Hughs CP, Danziger W et al. Volumetric measurements of the cerebrospinal fluid spaces in demented subjects and controls. Radiology 1982; 144: 535–538.
LeMay M. Radiologic changes of the aging brain and skull. Am J Radiol 1984; 143: 383–389.
Schwartz M, Creasey H, Grady CL et al. Computed tomographic analysis of brain morphometrics in 30 healthy men, aged 21 to 81 years. Ann Neurol 1985; 17: 146–157.
Pfefferbaum A, Zatz LM, Jernigan TL. Computer-interactive method for quantifying cerebrospinal fluid and tissue in brain CT scans: Effects of aging. J Comput Assist Tomogr 1986; 10: 571–578.
Drayer BP. Imaging of the aging brain. Radiology 1988; 166: 785–796.
Creasey H, Rapoport SI. The aging human brain. Ann Neurol 1985; 17: 2–10.
Jobst KA, Smith AD, Szatmari M et al. Detection in life of confirmed Alzheimer’s disease using a simple measurement of medial temporal lobe atrophy by computed tomography. Lancet 1992; 340: 1179–1183.
Jobst KA, Smith AD, Szatmari M et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer’s disease. Lancet 1994; 343: 829–830.
Pasquier F, Ball L, Lebert F et al. Determination of medial temporal lobe atrophy in early Alzheimer’s disease with computed tomography. Lancet 1994; 343: 861–862.
Tanna NK, Kohn MI, Horwich DN et al. Analysis of brain and cerebrospinal fluid volumes with MR imaging: Impact on PET data correction for atrophy. Radiology 1991; 178: 123–130.
Seab JP, Jagust WJ, Wong STS et al. Quantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med 1988; 8: 200–208.
Dahlbeck SW, McCluney KW, Yeakley JW et al. The interuncal distance: A new MR measurement for the hippocampal atrophy of Alzheimer disease. Am J Neuroradiol 1991; 12: 931–932.
Kesslak JP, Nalcioglu O, Cotman CW. Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology 1991; 41: 51–54.
Jack CR, Petersen RC, O’Brien PC et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology 1992; 42: 183–188.
Erkinjuntti T, Lee DH, Gao F et al. Temporal lobe atrophy on magnetic resonance imaging in the diagnosis of early Alzheimer’s disease. Arch Neurol 1993; 50: 305–310.
Laakso MP, Soininen H, Helkala E-L et al. Volumes of hippocampus and amygdala in the magnetic resonance imaging based diagnosis of early Alzheimer’s disease. In: Iqbal K, Mortimer JA, Winblad B et al., eds. Research Advances in Alzheimer’s Disease and Related Disorders, ed.: John Wiley & Sons Ltd, 1995: 181–188.
Jernigan TL, Salmon DP, Butters N et al. Cerebral structures on MRI: Part II. Specific changes in Alzheimer’s and Huntington’s diseases. Biol Psychiat 1991; 29: 68–81.
Rusinek H, de Leon MJ, George AE et al. Alzheimer disease: Measuring loss of cerebral gray matter with MR imaging. Radiology 1991; 178: 109–114.
Fazekas F, Chawluk JB, Alavi A et al. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. Am J Neuroradiol 1987; 8: 421–426.
Harrell LE, Duvall E, Folks DG et al. The relationship of high-intensity signals on magnetic resonance images to cognitive and psychiatric state in Alzheimer’s disease. Arch Neurol 1991; 48: 1136–1140.
Kumar A, Yousem D, Souder E et al. High-intensity signals in Alzheimer’s disease without cerebrovascular risk factors: A magnetic resonance imaging evaluation. Am J Psychiatry 1992; 149: 248–250.
Bradley WG, Waluch V, Brant-Zawadzki M et al. Patchy, periventricular white matter lesions in the elderly: A common observation during NMR imaging. Noninvas Med Imaging 1984; 1: 35–41.
Brant-Zawadski M, Fein G, Van Dyke C et al. MR imaging of the aging brain: patchy white-matter lesions and dementia. Am J Neuroradiol 1985; 6: 675–682.
George AE, de Leon MJ, Kalnin A et al. Leukoencephalopathy in normal and pathologic aging: II MRI of brain lucencies. Am J Neuroradiol 1986; 7: 561–570.
Rezek DL, Morris JC, Fulling KH et al. Periventricular white matter lucencies in senile dementia of the Alzheimer type and in normal aging. Neurology 1987; 37: 1365–1368.
Leys D, Soetaert G, Petit H et al. Periventricular and white matter magnetic resonance imaging hyperintensities do not differ between Alzheimer’s disease and normal aging. Arch Neurol 1990; 47: 524–527.
Ferris SH, De Leon MJ, Wolf AP et al. Positron emission tomography in dementia. Adv Neurol 1983; 38: 123–129.
Foster NL, Chase TN, Fedio P et al. Alzheimer’s disease: Focal cortical changes shown by positron emission tomography. Neurology 1983; 33: 961–965.
Friedland RP, Budinger TF, Koss E et al. Alzheimer’s disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 1983; 53: 235–240.
De Leon MJ, Ferris SH, George AE et al. Positron emission tomographic studies of aging and Alzheimer disease. Am J Neuroradiol 1983; 4: 568–571.
Grady CL, Haxby JV, Schlageter NL et al. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type. Neurology 1986; 36: 1390–1392.
Grady CL, Haxby JV, Horwitz B et al. Neuropsychological and cerebral metabolic function in early vs late onset dementia of the Alzheimer type. Neuropsychologia 1987; 25: 807–816.
Haxby JV, Grady CL, Koss E et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol 1990; 47: 753–760.
Azari NP, Rapoport SI, Grady CL et al. Patterns of interregional correlations of cerebral glucose metabolic rates in patients with dementia of the Alzheimer type. Neurodegeneration 1992; 1: 101–111.
Chawluk JB, Alavi A, Dann R et al. Positron emission tomography in aging and dementia: Effect of cerebral atrophy. J Nucl Med 1987; 28: 431–437.
DeCarli C, Atack JR, Ball MJ et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer’s disease patients. Neurodegeneration 1992; 1: 113–121.
Haxby JV, Duara R, Grady CL et al. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer’s disease. J Cereb Blood Flow Metab 1985; 5: 193–200.
Grady CL, Haxby JV, Horwitz B et al. A longitudinal study of the early neuro-psychological and cerebral changes in dementia of the Alzheimer type. J Clin Exp Neuropsychol 1988; 10: 576–596.
Kumar A, Schapiro MB, Haxby JV et al. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioural features. J Psychiatr Res 1990; 24: 97–109.
Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer’s disease. Lancet 1985; i: 228–230.
Cutler NR, Haxby JV, Duara R et al. Clinical history, brain metabolism, and neuropsychological function in Alzheimer’s disease. Ann Neurol 1985; 18: 298–309.
Duara R, Grady C, Haxby J et al. Positron emission tomography in Alzheimer’s disease. Neurology 1986; 36: 879–887.
Hubbard BM, Anderson JM. A quantitative study of cerebral atrophy in old age and senile dementia. J Neurol Sci 1981; 50: 135–145.
Hansen LA, Teresa R, Davies P et al. Neocortical morphometry, lesion count and choline acetyl transferase levels in the age spectrum of Alzheimer’s disease. Neurology 1988; 38: 48–54.
De la Monte S. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer’s disease. Ann Neurol 1989; 25: 450–459.
Mann DMA. The topographic distribution of brain atrophy in Alzheimer’s disease. Acta Neuropathol 1991; 83: 81–86.
Terry RD, Peck A, De Teresa R et al. Some morphometric aspects of the brain in senile dementia of the Alzheimer type. Ann Neurol 1981; 10: 184–192.
Mann DA, Yates PO, Marcyniuk B. Some morphometric observations on the cerebral cortex and hippocampus in presenile Alzheimer’s disease, senile dementia of Alzheimer type and Down’s syndrome in middle age. J Neurol Sci 1985; 69: 139–159.
Mille AH, Alston RL, Corsellis JAN. Variation with age in the volumes of grey and white matter in the cerebral hemispheres of man: measurements with an image analyser. Neuropath Appl Neurobiol 1980; 6: 119–132.
Regeur L, Jensen GB, Pakkenberg H et al. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer’s type. Neurobiol Aging 1994; 15: 347–352.
Tomlinson BE, Blessed G, Roth M. Observations on the brains of demented old people. J Neurol Sci 1970; 11: 205–242.
Neary D, Snowden JS, Mann DMA et al. Alzheimer’s disease: a correlative study. J Neurol Neurosurg Psychiatry 1986; 49: 229–237.
Duyckaerts C, Hauw JJ, Piette F et al. Cortical atrophy in senile dementia of Alzheimer type is mainly due to a decrease in cortical length. Acta Neuropathol 1985; 66: 72–74.
Shefer VF. Absolute numbers of neurones and thickness of the cerebral cortex during aging, senile and vascular dementia, and Pick’s and Alzheimer’s diseases. Neurosci Behav Physiol 1973; 6: 319–324.
Colon EJ. The cerebral cortex in presenile dementia. A quantitative analysis. Acta Neuropathol 1973; 23: 281–290.
Mountjoy CQ, Roth M, Evans NJR et al. Cortical neuronal counts in normal elderly controls and demented patients. Neurobiol Aging 1983; 4: 1–11.
Brun A, Englund E. Regional pattern of degeneration in Alzheimer’s disease: neuronal loss and histopathological grading. Histopathology 1981; 5: 549–564.
Hubbard BM, Anderson JM. Age-related variations in the neurone content of the cerebral cortex in senile dementia of Alzheimer type. Neuropath Appl Neurobiol 1985; 11: 369–382.
Tomlinson BE, Henderson G. Some quantitative cerebral findings in normal and demented old people. In: Terry RD, Gerhon S, eds. Neurobiology of Aging, ed. New York: Raven Press, 1976: 183–204.
Ball MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with aging and dementia. A quantitative study. Acta Neuropathol 1977; 37: 111–118.
Shefer VF. Hippocampal pathology as a possible factor in the pathogenesis of senile dementias. Neurosci Behav Physiol 1977; 8: 236–239.
Hyman BT, Damasio AR, van Hoesen GW et al. Alzheimer’s disease: cell-specific pathology isolates the hippocampal formation. Science 1984; 225: 1168–1170.
Doebler JA, Markesbery WR, Anthony A et al. Neuronal RNA in relation to neuronal loss and neurofibrillary pathology in the hippocampus in Alzheimer’s disease. J Neuropathol Exp Neurol 1987; 46: 28–39.
Davies DC, Horwood N, Isaacs SL et al. The effect of age and Alzheimer’s disease in pyramidal neurone density in the individual fields of the hippocampal formation. Acta Neuropathol 1992; 83: 510–517.
Cras P, Smith MA, Richey PL et al. Extracellular neurofibrillary tangles reflect neuronal loss and provide further evidence of extensive protein cross-linking in Alzheimer disease. Acta Neuropathol 1995; 89: 291–295.
Braak H, Braak E. On areas of transition between entorhinal allocortex and temporal isocortex within human brain. Normal morphology and laminar specific pathology. Acta Neuropathol 1985; 68: 325–332.
Hooper MW, Vogel FS. The limbic system in Alzheimer’s disease. Am J Pathol 1976; 85: 1–13.
Herzog AG, Kemper TL. Amygdaloid changes in aging and dementia. Arch Neurol 1980; 37: 625–629.
Saper CB, German DC, White CL. Neuronal pathology in the nucleus basalis and associated cell groups in senile dementia of Alzheimer type: possible role in cell loss. Neurology 1985; 35: 1089–1095.
Unger JW, McNeill TH, Lapham LL et al. Neuropeptides and neuropathology in the amygdala in Alzheimer’s disease: relationship between somatostatin, neuropeptide Y and subregional distribution of neuritic plaques. Brain Res 1988; 452: 293–302.
Brashear HR, Godec MS, Carlsen J. The distribution of neuritic plaques and acetylcholinesterase staining in the amygdala in Alzheimer’s disease. Neurology 1988; 38: 1694–1699.
Tsuchiya K, Kosaka K. Neuropathological study of the amygdala in presenile Alzheimer’s disease. J Neurol Sci 1990; 100: 165–173.
Murphy GM, Eng LF, Ellis WG et al. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down’s syndrome: a comparison with Alzheimer’s disease. Brain Res 1990; 537: 102–108.
Hyman BT, Van Hoesen GW, Damasio AR. Memory related neural systems in Alzheimer’s disease; An anatomic study. Neurology 1990; 40: 1721–1730.
Scott SA, DeKosky ST, Sparks DL et al. Amygdala cell loss and atrophy in Alzheimer’s disease. Ann Neurol 1992; 32: 555–563.
Kromer-Vogt LJ, Hyman BT, van Hoesen GW et al. Pathologic alterations in the amygdala in Alzheimer’s disease. Neuroscience 1990; 37: 377–385.
Mann DMA, Tucker CM, Yates PO. The topographic distribution of senile plaques and neurofibrillary tangles in the brains of non-demented persons of different ages. Neuropath Appl Neurobiol 1987; 13: 123–139.
Li Y-T, Woodruff-Pak DS, Trojanowski JQ. Amyloid plaques in the cerebellar cortex and the integrity of Purkinje cell dendrites. Neurobiol Aging 1993; 15: 1–9.
Mann DMA, Jones D, Prinja D et al. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down’s syndrome and Alzheimer’s disease. Acta Neuropathol 1990; 80: 318–327.
Nakano I, Hirano A. Loss of large neurones of the medial septal nucleus in an autopsy case of Alzheimer’s disease. J Neuropathol Exp Neurol 1981; 41: 341.
Whitehouse PJ, Price DL, Struble RG et al. Alzheimer’s disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237–1239.
Perry RH, Candy JM, Perry EK et al. Extensive loss of choline acetyl transferase activity is not related to neuronal loss in the nucleus basalis of Meynert in Alzheimer’s disease. Neurosi Lett 1982; 33: 311–315.
Candy JM, Perry RH, Perry EK et al. Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci 1983; 59: 277–289.
Wilcock GK, Esiri MM, Bowen DM et al. The nucleus basalis in Alzheimer’s disease; cell counts and cortical biochemistry. Neuropath Appl Neurobiol 1983; 9: 175–179.
Tagliavini F, Pilleri G. Basal nucleus of Meynert. J Neurol Sci 1983; 62: 243–260.
Mann DMA, Yates PO, Marcyniuk B. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer’s disease and their relationship to aging and the accumulation of lipofuscin pigment. Mech Aging Dev 1984; 25: 189–204.
Mann DMA, Yates PO, Marcyniuk B. A comparison of changes in the nucleus basalis and locus caeruleus in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1984; 47: 201–203.
Mann DMA, Yates PO, Marcyniuk B. Alzheimer’s presenile dementia, senile dementia of Alzheimer type and Down’s syndrome in middle age form an age-related continuum of pathological changes. Neuropath Appl Neurobiol 1984; 10: 185–207.
Arendt T, Bigl V, Arendt A et al. Loss of neurones in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoffs disease. Acta Neuropathol 1983; 61: 101–108.
Arendt T, Bigl V, Tennstedt A et al. Correlation between cortical plaque count and neuronal loss in nucleus basalis in Alzheimer’s disease. Neurosci Lett 1984; 48: 81–85.
Arendt T, Bigl V, Tennstedt A et al. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical target areas in Alzheimer’s disease. Neuroscience 1985; 14: 1–14.
Nagal T, McGeer PL, Peng JH et al. Choline acetyl transferase immunohistochemistry in brains of Alzheimer’s patients and controls. Neurosci Lett 1983; 36: 195–199.
McGeer PL, McGeer EG, Suzuki JS et al. Aging, Alzheimer’s disease and the cholinergic system of the basal forebrain. Neurology 1984; 34: 741–745.
Rogers JD, Brogan D, Mirra SS. The nucleus basalis of Meynert in neurological disease: A quantitative morphological study. Ann Neurol 1985; 17: 163–170.
Doucette R, Fisman M, Hachinsky VC et al. Cell loss from the nucleus basalis of Meynert in Alzheimer’s disease. Can J Neurol Sci 1986; 13: 435–440.
Doucette R, Ball MJ. Left-right symmetry of neuronal cell counts in the nucleus basalis of Meynert of control and of Alzheimer diseased brains. Brain Res 1987; 422: 357–360.
Ichimiya Y, Aral H, Kosaka K et al. Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer type dementia. Acta Neuropathol 1986; 70: 112–116.
Allen SJ, Dawbarn D, Wilcock GK. Morphometric immunochemical analysis of neurones in the nucleus basalis of Meynert in Alzheimer’s disease. Brain Res 1988; 454: 275–281.
De Lacalle S, Iraizoz I, Ma Gonzalo L. Differential changes in cell size and number in topographic subdivisions of human basal nucleus in normal aging. Neuroscience 1991; 43: 445–456.
Pearson RCA, Sofroniew MV, Cuello AC et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer’s type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res 1983; 289: 375–379.
Tomlinson BE, Irving D, Blessed G. Cell loss in the locus caeruleus in senile dementia of Alzheimer type. J Neurol Sci 1981; 49: 419–428.
Bondareff W, Mountjoy CQ, Roth M. Loss of neurones of origin of the adrenergic projection to cerebral cortex (nucleus locus caeruleus) in senile dementia. Neurology 1992; 32: 164–168.
Mann DMA, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982; 45: 113–119.
Mann DMA, Yates PO, Hawkes J. The pathology of the human locus caeruleus. Clin Neuropathol 1983; 2: 1–7.
Mann DMA, Yates PO, Marcyniuk B. Changes in Alzheimer’s disease in the magnocellular neurones of the supraoptic and paraventricular nuclei of the hypothalamus and their relationship to the noradrenergic deficit. Clin Neuropathol 1985; 4: 127–134.
Iversen LL, Rossor MN, Reynolds GP et al. Loss of pigmented dopamine β hydroxylase positive cells from locus caeruleus in senile dementia of Alzheimer’s type. Neurosci Lett 1983; 39: 95–100.
Chui HC, Mortimer JA, Slager UT et al. Pathological correlates of dementia in Parkinson’s disease. ArchNeurol 1986; 43: 991–995.
Marcyniuk B, Mann DMA, Yates PO. The topography of cell loss from locus caeruleus in Alzheimer’s disease. J Neurol Sci 1986; 76: 335–345.
Zweig RM, Ross CA, Hedreen JC et al. The neuropathology of aminergic nuclei in Alzheimer’s disease. Ann Neurol 1988; 24: 233–242.
Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson’s disease with and without dementia and depression. J Comp Neurol 1989; 287: 373–392.
Strong R, Huang JS, Huang SS et al. Degeneration of the cholinergic innervation of the locus caeruleus in Alzheimer’s disease. Brain Res 1991; 542: 23–28.
German DC, Manaye KF, White CL et al. Disease specific patterns of locus caeruleus cell loss: Parkinson disease, Alzheimer’s disease and Down’s syndrome. Ann Neurol 1992; 32: 667–676.
Giess R, Schlote W. Localisation and association of pathomorphological changes at the brainstem in Alzheimer’s disease. Mech Aging Dev 1995; 84: 209–226.
Hoogendijk WJG, Pool CW, Troost D et al. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Brain 1995; 118: 131–143.
Ishii T. Distribution of Alzheimer’s neurofibrillary changes in brain stem and hypothalamus of senile dementia. Acta Neuropathol 1966; 38: 181–187.
Hirano A, Zimmerman HM. Alzheimer’s neurofibrillary changes. A topographic study. Arch Neurol 1962; 7: 73–88.
Curcio CA, Kemper T. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density. J Neuropathol Exp Neurol 1985; 43: 359–368.
Yamamoto T, Hirano A. Nucleus raphe dorsalis in Alzheimer’s disease: neurofibrillary tangles and loss of large neurons. Ann Neurol 1985; 17: 573–577.
Tabaton M, Schenone A, Romagnoli P et al. A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer’s disease. Acta Neuropathol 1985; 68: 213–223.
Jellinger K. Quantitative changes in some subcortical nuclei in aging, Alzheimer’s disease and Parkinson’s disease. Neurobiol Aging 1987; 8: 556–561.
Mann DMA, Yates PO, Marcyniuk B. Dopaminergic neurotransmitter systems with Alzheimer’s disease and Down’s syndrome at middle age. J Neurol Neurosurg Psychiatry 1987; 50: 341–344.
Gibb WRG, Mountjoy CQ, Mann DMA et al. The substantia nigra and ventral tegmental area in Alzheimer’s disease and Down’s syndrome. J Neurol Neurosurg Psychiatry 1989; 52: 193–200.
Mann DMA, Yates PO, Marcyniuk B. Monoaminergic neurotransmitter systems in presenile Alzheimer’s disease and in senile dementia of Alzheimer type. Clin Neuropathol 1984; 3: 199–205.
German DC, White CL, Sparkman DR. Alzheimer’s disease: neurofibrillary tangles in nuclei that project to the cerebral cortex. Neuroscience 1987; 21: 305–312.
Lehericy S, Hirsch EC, Hersh LB et al. Cholinergic neuronal loss in the globus pallidus of Alzheimer’s disease patients. Neurosci Lett 1991; 123: 152–155.
Lehericy S, Hirsch EC, Cervera P et al. Selective loss of cholinergic neurones in the ventral striatum of patients with AD. Proc Natl Acad Sci (USA) 1989; 86: 8580–8584.
Xuereb JH, Perry EK, Candy JM et al. Parameters of cholinergic neurotransmission in the thalamus in Parkinson’s disease and Alzheimer’s disease. J Neurol 1990; 99: 185–197.
Oyanagi K, Takahashi H, Wakabayashi K et al. Selective involvement of large neurones in the neostriatum of Alzheimer’s disease and senile dementia: A morphometric investigation. Brain Res 1987; 411: 205–211.
Oyanagi K, Takahashi H, Wakayashi K et al. Correlative decrease of large neurones in the neostriatum and basal nucleus of Meynert in Alzheimer’s disease. Brain Res 1989; 504: 354–357.
Oyanagi K, Takahashi H, Wakabayashi K et al. Large neurons in the neostriatum in Alzheimer’s disease and progressive supranuclear palsy: a topographic, histologic and ultrastructural investigation. Brain Res 1991; 544: 221–226.
Masliah E, Terry RD, Buzsaki G. Thalamic nuclei in Alzheimer’s disease—evidence against the cholinergic hypothesis of plaque formation. Brain Res 1989; 493: 240–246.
Tourtellotte WG, Van Hoesen GW, Hyman BT et al. Alz-50 immunoreactivity in the thalamic reticular nucleus in Alzheimer’s disease. Brain Res 1989; 515: 227–234.
Braak H, Braak E. Alzheimer’s disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991; 81: 261–268.
Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res 1985; 342: 37–44.
Kremer B, Swaab D, Bots G et al. The hypothalamic lateral tuberal nucleus in Alzheimer’s disease. Ann Neurol 1991; 29: 279–284.
Zhou J-N, Hofman MA, Swaab DF. VIP neurons in the human SCN in relation to sex, age, and Alzheimer’s disease. Neurobiol Aging 1995; 16: 571–576.
Wilkinson A, Davies I. The influence of age and dementia on the neurone population of the mammillary bodies. Age Aging 1978; 7: 151–160.
Scheff SW, Price DA. Synapse loss in the temporal lobe in Alzheimer’s disease. Ann Neurol 1993; 33: 190–199.
Scheff SW, DeKosky ST, Price DA. A quantitative assessment of cortical synaptic density in Alzheimer’s disease. Neurobiol Aging 1990; 11: 29–37.
Davies CA, Mann DMA, Sumpter PQ et al. A quantitative analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. J Neurol Sci 1987; 78: 151–164.
Gibson PH. EM Study of the numbers of cortical synapses in the brains of aging people and people with Alzheimer-type dementia. Acta Neuropathol 1983; 62: 127–133.
DeKosky ST, Scheff SW. Synpase loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 1990; 27: 457–464.
Masliah E, Hansen T, Mallory M et al. Immunoelectron microscopic study of synaptic pathology in Alzheimer’s disease. Acta Neuropathol 1991; 81: 428–433.
Mann DMA, Yates PO. Neurotransmitter deficits in Alzheimer’s disease and in other dementing disorders. Hum Neurobiol 1986; 5: 147–158.
Hedera P, Whitehouse PJ. Neurotransmitters in neurodegeneration. In: Calne DB, ed. Neurodegenerative Diseases. Philadelphia, London, Toronto, Montreal, Sydney, Tokyo: WB Saunders Co, 1994: 97–117.
Parker WD, Parks J, Filley CM et al. Electron chain transfer defects in Alzheimer brain. Neurology 1994; 44: 1090–1096.
Simonian NA, Hyman BT. Functional alterations in Alzheimer’s disease: Diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 1993; 52: 580–585.
Mutisya EM, Bowling AC, Walker LC et al. Impaired energy metabolism in aging and Alzheimer’s disease. Soc Neurosci Abs 1993; 19: 1474.
Simonian NA, Hyman BT. Functional alterations in Alzheimer’s disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol 1994; 53: 508–512.
Sims NR, Finegan JM, Blass JP. Altered metabolic properties of cultured skin fibro-blasts in Alzheimer’s disease. Ann Neurol 1987; 21: 451–457.
Blass JP, Gibson GE, Sheu K-FR et al. Mitochondria, aging and neurological diseases. In: Zatta P, Nicolini M, eds. Non-Neuronal Cells in Alzheimer’s Disease. Singapore, New Jersey, London, Hong Kong: World Scientific, 1995: 95–107.
Sumpter PQ, Mann DMA, Davies CA et al. An ultrastructural analysis of the effects of accumulation of neurofibrillary tangle in pyramidal cells of the cerebral cortex in Alzheimer’s disease. Neuropath Appl Neurobiol 1986; 12: 305–319.
Mann DMA, Yates PO, Barton CM. Cytophotometric mapping of neuronal changes in senile dementia. J Neurol Neurosurg Psychiatry 1977; 40: 299–302.
Mann DMA, Sinclair KGA. The quantitative assessment of lipofuscin pigment, cytoplasmic RNA and nucleolar volume in senile dementia. Neuropath Appl Neurobiol 1978; 4: 129–135.
Mann DMA, Yates PO. The relationship between formation of senile plaques and neurofibrillary tangles and changes in nerve cell metabolism in Alzheimer-type dementia. Mech Aging Dev 1981; 17: 395–401.
Doebler JA, Markesbery WR, Anthony A et al. Neuronal RNA in relation to Alz-50 immunoreactivity in Alzheimer’s disease. Ann Neurol 1988; 23: 20–24.
Doebler JA, Rhoads RE, Anthony A et al. Neuronal RNA in Pick’s and Alzheimer’s diseases. Arch Neurol 1989; 46: 134–137.
Mann DMA, Neary D, Yates PO et al. Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer’s disease. Neuropath Appl Neurobiol 1981; 7: 37–47.
Mann DMA, Neary D, Yates PO et al. Alterations in protein synthetic capability in nerve cells in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1981; 44: 97–102.
Scheibel ME, Lindsay RD, Tomiyasu U et al. Progressive dendritic changes in the aging human cortex. Exp Neurol 1975; 47: 392–403.
Scheibel ME, Lindsay RD, Tomiyasu U et al. Progressive dendritic changes in the aging human limbic system. Exp Neurol 1976; 53: 420–430.
Scheibel ME, Tomiyasu U, Scheibel AB. The aging human Betz cell. Exp Neurol 1977; 56: 598–609.
Buell SJ, Coleman PD. Dendritic growth in the aged human brain and fallure of growth in senile dementia. Science 1979; 206: 854–856.
Buell SJ, Coleman PD. Quantitative evidence for selective dendritic growth in normal human aging but not in senile dementia. Brain Res 1981; 214: 23–41.
Flood DG, Buell SJ, Horwitz GJ et al. Dendritic extent in human dentate gyrus granule cells in normal aging and senile dementia. Brain Res 1987; 402: 205–216.
Flood DG, Guarnaccia M, Coleman PD. Dendritic extent in human CA2/3 hippoc-ampal pyramidal neurones in normal aging and senile dementia. Brain Res 1987; 409: 88–96.
Braak H, Braak E, Grundke-Iqbal I et al. Occurrence of neuropil threads in the senile human brain and in Alzheimer’s disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett 1986; 65: 351–355.
Ihara Y. Massive somatodendritic sprouting of cortical neurons in Alzheimer’s disease. Brain Res 1988; 459: 138–144.
Terry RD, Masliah E, Salmon P et al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991; 30: 572–580.
Masliah E, Terry RD, DeTeresa RM et al. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 1989; 103: 234–239.
Honer WG, Dickson DW, Gleeson J et al. Regional synaptic pathology in Alzheimer’s pathology. Neurobiol Aging 1992; 13: 375–382.
Hamos JE, DeGennaro LJ, Drachman DA. Synaptic loss in Alzheimer’s disease and other dementias. Neurology 1989; 39: 355–361.
Zhan S-S, Beyreuther K, Schmitt HP. Quantitative assessment of the synaptophysin immuno-reactivity of the cortical neuropil in various neurodegenerative disorders with dementia. Dementia 1993; 4: 66–74.
Brun A, Liu X, Erikson C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer’s disease and in frontal lobe degeneration. Neurodegeneration 1995; 4: 171–177.
Heinonen O, Lehtovirta M, Soininen H et al. Alzheimer pathology of patients carrying apolipoprotein E E4 allele. Neurobiol Aging 1995; 16: 505–513.
Masliah E, Terry RD, Mallory M et al. Diffuse plaques do not accentuate synapse loss in Alzheimer’s disease. Am J Pathol 1990; 137: 1293–1297.
Wisniewski HM, Wegiel J, Kotula L. Some neuropathological aspects of Alzheimer’s disease and its relevance to other disciplines. Neuropath Appl Neurobiol 1996; 22: 3–11.
Rebeck GW, Reiter JS, Strickland DK et al. Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron 1993; 11: 575–580.
Schmechel D, Saunders AM, Strittmatter WJ et al. Increased amyloid β peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci (USA) 1993; 90: 9649–9653.
Benjamin R, Leake A, Ince PG et al. Effects of apolipoprotein E genotype on cortical neuropathology in senile dementia of the Lewy body type and Alzheimer’s disease. Neurodegeneration 1995; 4: 443–448.
Harrington CR, Louwagie J, Rossau R et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types. Am J Pathol 1994; 145: 1472–1484.
Esiri MM, Pearson RCA, Powell TPS. Thecortex of the primary auditory area in Alzheimer’s disease. Brain Res 1986; 366: 385–387.
Pearson RCA, Hiorns RW, Wilcock GK et al. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer’s disease. Proc Natl Acad Sci (USA) 1985; 82: 4531–4534.
Beach TG, McGeer EG. Lamina-specific arrangement of astrocytic gliosis and senile plaques in Alzheimer’s disease visual cortex. Brain Res 1988; 463: 357–361.
Braak H, Braak E, Kalus P. Alzheimer’s disease: areal and laminar pathology in the occipital isocortex. Atta Neuropathol 1989; 77:494–506.
Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease. J Neurosci 1985; 5: 2801–2808.
Lewis DA, Campbell MJ, Terry RD et al. Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer’s disease: A quantitative study of visual and auditory cortices. J Neurosci 1987; 7: 1799–1808.
Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239–259.
Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathologic changes. Neurosci Lett 1993; 153: 131–135.
Giannakopoulos P, Hof PR, Mottier S et al. Neuropathological changes in the cerebral cortex of 1258 cases from a geriatric hospital: retrospective clinicopathological evaluation of a 10-year autopsy population. Acta Neuropathol 1994; 87: 456–468.
Mann DMA, Younis N, Jones D et al. The time course of pathological events concerned with plaque formation in Down’s syndrome with particular reference to the involvement of microglial cells. Neurodegeneration 1992; 1: 201–215.
Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type pathologic changes in non-demented elderly individuals matches the pattern in Alzheimer’s disease. Neurology 1992; 42: 1681–1688.
Mann DMA, Tucker CM, Yates PO. Alzheimer’s disease: an olfactory connection? Mech Aging Dev 1988; 42: 1–15.
Reyes PF, Golden GT, Fagel PL et al. The prepiriform cortex in dementia of the Alzheimer type. Arch Neurol 1987; 44: 644–645.
Esiri MM, Wilcock GK. The olfactory bulbs in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1984; 47: 56–60.
Ohm TG, Braak H. Olfactory bulb changes in Alzheimer’s disease. Acta Neuropathol 1987; 73: 365–369.
Armstrong RA, Slaven A. Does the neurodegeneration of Alzheimer’s disease spread between visual cortical regions B17 and B18 via the feedforward or feedback short cortico-cortical projections? Neurodegeneration 1994; 3: 191–196.
De LaCoste M-C, White CL. The role of cortical connectivity in Alzheimer’s disease pathogenesis: A review and model system. Neurobiol Aging 1993; 14: 1–16.
Ikeda S-I, Allsop D, Glenner GG. The morphology and distribution of plaque and related deposits in the brains of Alzheimer’s disease and control cases: an immunohistochemical study using amyloid β protein antibody. Lab Invest 1989; 60: 113–122.
Bugiani O, Giaccone G, Frangione B et al. Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neurosci Lett 1989; 103: 262–268.
Tagliavini F, Giaccone G, Frangione B et al. Preamyloid deposits in the cerebral cortex of patients with Alzheimer’s disease and non demented individuals. Neurosci Lett 1988; 93: 191–196.
Ogomori K, Kitamoto T, Tateishi J et al. β amyloid protein is widely distributed in the central nervous system of patients with Alzheimer’s disease. Am J Pathol 1989; 134: 243–251.
Yamaguchi H, Hirai S, Morimatsu M et al. Diffuse type of senile plaques in the brains of Alzheimer-type dementia. Acta Neuropathol 1988; 77: 113–119.
Yamaguchi H, Hirai S, Morimatsu M et al. A variety of cerebral amyloid deposits with brains of Alzheimer-type dementia demonstrated by β-protein immunostaining. Acta Neuropathol 1988; 76: 541–549.
Yamaguchi H, Hirai S, Morimatsu M et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia detected by β-protein immunostaining. Acta Neuropathol 1989; 77: 314–319.
Wisniewski HM, Bancher C, Barcikowska M et al. Spectrum of morphological appearance of amyloid deposits in Alzheimer’s disease. Acta Neuropathol 1989; 78: 337–347.
Barcikowska M, Wisniewski HM, Bancher C et al. About the presence of paired helical filaments in dystrophic neuntes participating in the plaque formation. Acta Neuropathol 1989; 78: 225–231.
Price JL, Davis PB, Morris JC et al. The distribution of plaques, tangles and related immunohistochemical markers in healthy aging and Alzheimer’s disease. Neurobiol Aging 1991; 12: 295–312.
Giaccone G, Tagliavini F, Linoli G et al. Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett 1989; 97: 232–238.
Brilliant M, Elble RJ, Ghobrial M et al. Distribution of amyloid in the brainstem of patients with Alzheimer disease. Neurosci Lett 1992; 148: 23–26.
Suenaga T, Hirano A, Llena JF et al. Modified Bielschowsky and immunocytochemical studies on cerebellar plaques in Alzheimer’s disease. J Neuropathol Exp Neurol 1990; 49: 31–40.
Suenaga T, Hirano A, Llena JF et al. Modified Bielschowsky staining and immunohistochemical studies on striatal plaques in Alzheimer’s disease. Acta Neuropathol 1990; 80: 280–286.
Cole G, Williams P, Alldrick D et al. Amyloid plaques in the cerebellum in Alzheimer’s disease. Clin Neuropathol 1989; 4: 188–191.
Cole G, Neal JW, Singrao SK et al. The distribution of amyloid plaques in the cerebellum and brain stem in Down’s syndrome and Alzheimer’s disease: a light microscopical analysis. Acta Neuropathol 1993; 85: 542–552.
Joachim CL, Morris JH, Selkoe DJ. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer’s disease. Am J Pathol 1989; 135: 309–319.
Mann DMA, Iwatsubo T, Snowden JS. Atypical amyloid (Aβ) deposition in the cerebellum in Alzheimer’s disease: an immunohistochemical study using end-specific Aβmonoclonal antibodies. Acta Neuropathol 1996; 91: 647–653.
Leuba G, Salni K. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer’s disease. Neuropath Appl Neurobiol 1995; 21: 410–422.
Iseki E, Matsushita M, Kosaka K et al. Distribution and morphology of brain stem plaques in Alzheimer’s disease. Acta Neuropathol 1989; 78: 131–136.
Standaert DG, Lee VM-Y, Greenberg BD et al. Molecular features of hypothalamic plaques in Alzheimer’s disease. Am J Pathol 1991; 139: 681–691.
MacKenzie IRA, McKelvie PA, Beyreuther K et al. βA4 amyloid protein deposition in the cerebellum in Alzheimer’s disease and Down’s syndrome. Dementia 1991; 2: 237–242.
Braak H, Braak E, Bohl J et al. Alzheimer’s disease: amyloid plaques in the cerebellum. J Neurol Sci 1989; 93: 277–287.
McKee AC, Kosik KS, Kowall NW. Neuritic pathology and dementia in Alzheimer’s disease. Ann Neurol 1991; 30: 156–165.
Pro JD, Smith CH, Sumi SM. Presenile Alzheimer disease: amyloid plaques in the cerebellum. Neurology 1980; 30: 820–825.
Morioka E. Senile amyloid changes in the cerebellum with special reference to senile plaques and amyloid angiopathy. Neuropathol 1985; 6: 313–323.
Akiyama H, Yamada T, McGeer PL et al. Columnar arrangement of β-amyloid protein deposits in the cerebral cortex of patients with Alzheimer’s disease. Acta Neuropathol 1993; 85: 400–403.
Kosik KS, Rogers J, Kowall NW. Senile plaques are located between apical dendritic clusters. J Neuropathol Exp Neurol 1987; 46: 1–11.
Duyckaerts C, Hauw J-J, Bastenaire F et al. Laminar distribution of neocortical senile plaques in senile dementia of the Alzheimer type. Acta Neuropathol 1986; 70: 249–256.
Gentleman SM, Allsop D, Bruton CJ et al. Quantitative differences in the deposition of βA4 protein in the sulci and gyri of frontal temporal isocortex in Alzheimer’s disease. Neurosci Lett 1992; 136: 27–30.
Clinton J, Roberts GW, Gentleman SM et al. Differential pattern of β-amyloid protein deposition within cortical sulci and gyri in Alzheimer’s disease. Neuropath Appl Neurobiol 1993; 19: 277–281.
McKenzie JE, Gentleman SM, Royston MC et al. Quantification of plaque types in sulci and gyri of medial frontal lobe in patients with Alzheimer’s disease. Neurosci Lett 1992; 143: 23–26.
Hassler D. Arterial deformities in senile brains. Acta Neuropathol 1967; 8: 219–229.
Ravens JR. Vascular changes in the human senile brain. In: Cervos-Navarra J, ed. Pathology of Cerebrospinal Microcirculation, ed. New York: Raven Press, 1978: 487–501.
Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer’s disease. Acta Neuropathol 1990; 79: 672–679.
Buee L, Hof PR, Bouras C et al. Pathological alterations of the cerebral microvasculature in Alzheimer’s disease and related dementing disorders. Acta Neuropathol 1994; 87: 469–480.
Mann DMA, Eaves NR, Marcyniuk B et al. Quantitative changes in cerebral cortical microvasculature in aging and dementia. Neurobiol Aging 1986; 7: 321–330.
Bell MA, Ball MJ. Morphometric comparison of hippocampal microvasculature in aging and demented people: diameter and densities. Acta Neuropathol 1981; 53: 299–318.
Kidd M. Alzheimer’s Disease-An electron microscopical study. Brain 1964; 87: 307–318.
Mancardi GL, Perdelli F, Rivano C et al. Thickening of the basement membrane of cortical capillaries in Alzheimer’s disease. Acta Neuropathol 1980; 49: 79–83.
Scheibel AB, Duong T, Jacobs R. Alzheimer’s disease as a capillary dementia. Ann Med 1989; 21: 103–107.
Mann DMA, Purkiss MS, Bonshek RE et al. Lectin histochemistry of cerebral microvessels in aging, Alzheimer’s disease and Down’s syndrome. Neurobiol Aging 1992; 13: 137–143.
Mancardi GL, Liwnicz BH, Mandybur TI. Fibrous astrocytes in Alzheimer’s disease and senile dementia of Alzheimer’s type. Acta Neuropathol 1983; 61: 76–80.
Schechter R, Yen S-HC, Terry RD. Fibrous astrocytes in senile dementia of the Alzheimer type. J Neuropathol Exp Neurol 1981; 40: 95–101.
Alafuzoff I, Adolfsson R, Bucht G et al. Albumin and immunoglobulin in plasma and cerebrospinal fluid, and blood-cerebrospinal fluid barrier function in patients with dementia of Alzheimer type and multi-infarct dementia. J Neurol Sci 1983; 60: 465–472.
Blennow K, Wallin A, Fredman P et al. Blood-brain barrier disturbance in patients with Alzheimer’s disease is related to vascular factors. Acta Neurol Scand 1990; 81: 323–326.
Elovaara I, Icen A, Palo J et al. CSF in Alzheimer’s disease: Studies on blood-brain barrier function and intrathecal protein synthesis. J Neurol Sci 1985; 70: 73–80.
Mann DMA, Davies JS, Yates PO et al. Immunohistochemical staining of senile plaques. Neuropath Appl Neurobiol 1982; 8: 55–61.
Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Ann NY Acad Sci 1982; 396: 119–129.
Ishii T, Haga S. Immuno-electron microscopic localization of immunoglobulins in amyloid fibrils of senile plaques. Acta Neuropathol 1976; 36: 243–249.
Alafuzoff I, Adolfsson R, Grundke-Iqbal I et al. Peri vascular deposits of serum proteins in cerebral cortex in vascular dementia. Acta Neuropathol 1985; 66: 292–298.
Wallin A, Blennow K, Fredman P et al. Blood-brain barrier function in vascular dementia. Acta Neurol Scand 1990; 81: 318–322.
Glenner GG. On causative theories in Alzheimer’s disease. Hum Pathol 1985; 16: 433–435.
Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke 1987; 18: 311–324.
Esiri M, Wilcock GK. Cerebral amyloid angiopathy in dementia and old age. J Neurol Neurosurg Psychiatry 1986; 49: 1221–1226.
Simchowitz T. Histologische Studien uber die senile demenz. In: Nissl F, Alzheimer A, eds. Histologische und Histopathologische Arbeiten. Jena: Gustav Fischer, 1911: 267–444.
Tomlinson BE, Kitchener D. Granulovacuolar degeneration of hippocampal pyramidal cells. J Pathol 1971; 106: 165–185.
Ball MJ. Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in the hippocampal cortex of aging and demented patients. A quantitative study. Acta Neuropathol 1978; 42: 73–80.
Ball MJ, Lo P. Granulovacuolar degeneration in the aging brain and in dementia. J Neuropathol Exp Neurol 1977; 36: 474–487.
Xu M, Shibayama H, Kobayashi H et al. Granuolovacuolar degeneration in the hippocampal cortex of aging and demented patients-a quantitative study. Acta Neuropathol 1992; 85: 1–9.
Woodward JS. Clinicopathological significance of granulovacuolar degeneration in Alzheimer’s disease. J Neuropathol Exp Neurol 1962; 21: 85–91.
Gibson PH, Tomlinson BE. Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer’s disease. J Neurol Sci 1977; 33: 199–206.
Ogata J, Budzilovitch GN, Cravioto H. A study of rod-like structures (Hirano bodies) in 240 normal and pathological brains. Acta Neuropathol 1972; 21: 61–67.
Berk ML, Finkelstein JA. An autoradiographie determination of the afferent projections of the suprachiasmatic nucleus of the hypothalamus. Brain Res 1981; 226: 1–13.
Goudsmit E, Hopman MA, Fliers E et al. The supraoptic and paraventricular nuclei of the human hypothalamus in relation to sex, age and Alzheimer’s disease. Neurobiol Aging 1990; 11: 529–536.
Rudelli RD, Ambler MW, Wisniewski HM. Morphology and distribution of Alzheimer neuritic (senile) and amyloid plaques in striatum and diencephalon. Acta Neuropathol 1984; 64: 273–281.
Simpson J, Yates CM, Watts AG et al. Congo Red birefringent structures in the hypothalamus in senile dementia of the Alzheimer type. Neuropath Appl Neurobiol 1988; 14: 381–393.
McDuff T, Sumi SM. Subcortical degeneration in Alzheimer’s disease. Neurology 1985; 35: 123–126.
Saper CB, German DC. Hypothalamic pathology in Alzheimer’s disease. Neurosci Lett 1987; 74: 364–370.
Mann DMA. The pathological association between Down syndrome and Alzheimer disease. Mech Aging Dev 1988; 43: 99–136.
Mann DMA. Alzheimer’s disease and Down’s syndrome. Histopath 1988; 13: 125–138.
Mann DMA, Esiri MM. Regional acquisition of plaques and tangles in Down’s syndrome patients under 50 years of age. J Neurol Sci 1989; 89: 169–179.
Allsop D, Haga S-I, Haga C et al. Early senile plaques in Down’s syndrome brains show a clear relationship with cell bodies of neurones. Neuropath Appl Neurobiol 1989; 15: 531–542.
Rumble B, Retallack R, Hilbich C et al. Amyloid (A4) protein and its precursor in Down’s syndrome and Alzheimer’s disease. N Engl J Med 1989; 320: 1446–1452.
Lemere CA, Blusztajn JK, Yamaguchi H et al. Sequence of deposition of heterogeneous amyloid β-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 1996; 3: 16–32.
Royston MC, Kodical NS, Mann DMA et al. Quantitative analysis of β-amyloid deposition in Down’s syndrome using computerized image analysis. Neurodegeneration 1994; 3: 43–51.
Mann DMA, Iwatsubo T. Diffuse plaques in the cerebellum and corpus striatum in Down’s syndrome contain amyloid β protein (Aβ) only in the form of Aβ42(43). Neurodegeneration 1996; 5: 115–120.
Kida E, Wisniewski KE, Wisniewski HM. Early amyloid-β deposits show different immunoreactivity to the amino-and carboxy-terminal regions of β-peptide in both Alzheimer’s disease and Down’s syndrome brain. Neurosci Lett 1995; 193: 1–4.
Motte J, Williams RS. Age-related changes in the density and morphology of plaques and neurofibrillary tangles in Down’s syndrome brains. Acta Neuropathol 1989; 77: 535–546.
Mann DMA, Brown AMT, Prinja D et al. An analysis of the morphology of senile plaques in Down’s syndrome patients of different ages using immunocytochemical and lectin histochemical methods. Neuropath Appl Neurobiol 1989; 15: 317–329.
Mann DMA, Iwatsubo T, Fukumoto H et al. Microglial cells and amyloid β protein (Aβ) deposition; association with Aβ40 containing plaques. Acta Neuropath 1995; 90: 472–477.
Wisniewski HM, Rabe A. Discrepancy between Alzheimer type neuropathology and dementia in persons with Down’s syndrome. Ann NY Acad Sci 1986; 477: 247–259.
Oliver C, Holland AJ. Down’s syndrome and Alzheimer’s disease: a review. Psychol Med 1986; 16: 307–322.
Mann DMA, Yates PO, Marcyniuk B et al. Loss of nerve cells from cortical and subcortical areas in Down’s syndrome patients at middle age: quantitative comparisons with younger Down’s patients and patients with Alzheimer’s disease. J Neurol Sci 1987; 80: 79–89.
Iwatsubo T, Mann DMA, Odaka A et al. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann Neurol 1995; 37: 294–299.
Davies CA, Mann DMA. Co-localization of apolipoprotein E and amyloid β protein in Down’s syndrome. Ann Neurol 1996; (in press):.
Snow AD, Mar H, Nochlin D et al. Early accumulation of heparan sulphate in neurones and in the β amyloid protein containing lesions of Alzheimer’s disease and Down’s syndrome. Am J Pathol 1990; 137: 1253–1270.
Kalaria RN, Perry G. Amyloid P component and other acute phase proteins associated with cerebellar Aβdeposits in Alzheimer’s disease. Brain Res 1993; 631: 151–155.
Snow AD, Seikiguchi RT, Nochlin D et al. Heparan sulphate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer’s disease brain. Am J Pathol 1994; 144: 337–347.
Teller JK, Russo C, de Busk LM et al. Presence of soluble amyloid β peptide precedes amyloid plaque formation in Down’s syndrome. Nature Medicine 1996; 2: 93–95.
Fukumoto H, Asami-Odaka A, Suzuki N et al. Amyloid β protein (Aβ) deposition in normal aging has the same characteristics as that in Alzheimer’s disease: predominance of Aβ42(43) and association of Aβ40 with cored plaques. Am J Pathol 1996; 148: 259–265.
Byrne EJ, Lennox G, Godwin-Austen RB et al. Dementia associated with cortical Lewy bodies: proposed clinical diagnostic criteria. Dementia 1991; 2: 283–284.
McKeith IG, Perry RH, Fairbairn AF et al. Clinical diagnostic criteria for Lewy body dementia. Dementia 1992; 3: 251–252.
Dickson DW, Crystal H, Mattiace LA et al. Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques. Acta Neuropathol 1989; 78: 572–584.
Dickson DW, Ruan D, Crystal H et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLDB) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2–3 neurites specific to DLDB. Neurology 1991; 41: 1402–1409.
Gentleman SM, Williams B, Royston MC et al. Quantification of β/A4 protein deposition in the medial temporal lobe: a comparison of Alzheimer’s disease and senile dementia of the Lewy body type. Neurosci Lett 1992; 142: 9–12.
Ince P, Irving D, MacArthur F et al. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson’s disease and non-demented elderly control patients. J Neurol Sci 1991; 106: 142–152.
Perry RH, Irving D, Blessed G et al. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci 1990; 95: 119–139.
Hansen L, Salmon D, Galasko D et al. The Lewy body variant of Alzheimer’s disease: A clinical and pathological entity. Neurology 1990; 40: 1–8.
Lippa CF, Smith TW, Swearer JM. Alzheimer’s disease and Lewy body disease: A comparative clinicopathological study. Ann Neurol 1994; 35: 81–88.
Mann DMA, Snowden JS. The topographic distribution of brain atrophy in cortical Lewy body disease: comparison with Alzheimer’s disease. Acta Neuropathol 1995; 89: 178–183.
Benjamin R, Leake A, Edwardson JA et al. Apolipoprotein E genes in Lewy body and Parkinson’s disease. Lancet 1994; 343: 1565.
Pickering-Brown S, Mann DMA, Bourke JP et al. Apolipoprotein E4 and Alzheimer’s disease pathology in Lewy body disease and in other β-amyloid forming diseases. Lancet 1994; 343: 1155.
Galasko D, Saitoh T, Xia Y et al. The apolipoprotein E allele E4 is over-represented in patients with the Lewy body variant of Alzheimer’s disease. Neurology 1994; 44: 1950–1951.
Luyendijk W, Bots TAM, Vegtner-van der Vlis M et al. Hereditary cerebral haemorrhage caused by cortical amyloid angiopathy. J Neurol Sci 1988; 85: 267–280.
Van Duinen SG, Castano EM, Prelli F et al. Hereditary cerebral haemorrhage with amyloidosis in patients of the Dutch origin is related to Alzheimer disease. Proc Natl Acad Sci (USA) 1987; 84: 5991–5994.
Maat-Schieman MLC, Van Duinen SG, Haan J et al. Morphology of cerebral plaque-like lesions in hereditary cerebral haemorrhage with amyloidosis (Dutch). Acta Neuropathol 1992; 84: 674–679.
Maat-Schieman MLC, Rozemuller AJ, Van Duinen SG et al. Microglia in diffuse plaques in hereditary cerebral haemorrhage with amyloidosis (Dutch). An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53: 483–491.
Maat-Schieman MLC, Radder CM, Van Duinen SG et al. Hereditary cerebral haemorrhage with amyloidosis (Dutch): a model for argyrophilic plaque formation without neurofibrillary pathology. Acta Neuropathol 1994; 88: 371–378.
Rozemuller JM, Bots TAM, Roos RAC et al. Acute phase proteins but not activated microglial cells are present in parenchymal β/A4 deposits in the brains of patients with hereditary cerebral haemorrhage with amyloidosis-Dutch type. Neurosci Lett 1992; 140: 137–140.
Mann DMA, Iwatsubo T, Ihara Y et al. Predominant deposition of Aβ42(43) in plaques in cases of Alzheimer’s disease and hereditary cerebral haemorrhage associated with mutations in the amyloid precursor protein gene. Am J Pathol 1996; 148: 1257–1266.
Wisniewski T, Frangione B. Molecular biology of Alzheimer’s amyloid-Dutch variant, Mol. Neurobiol 1992; 6: 75–86.
Levy E, Carman MD, Fernandez-Madrid IJ et al. Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral haemorrhage, Dutch type. Science 1990; 248: 1124–1126.
Van Broeckhoven C, Haan J, Bakker E et al. Amyloid β protein precursor gene and hereditary cerebral hemorrhage with amyloidosis (Dutch). Science 1990; 248: 1120–1128.
Clements A, Walsh DM, Williams CH et al. Effects of the mutations Glu22 to Gln and Ala21 to Gly on the aggregation of a synthetic fragment of the Alzheimer’s amyloid β/A4 peptide. Neurosci Lett 1993; 161: 17–20.
Fabian H, Szendrei GI, Mantsch HH et al. Comparative analysis of human and Dutchtype Alzheimer β-amyloid peptides by infrared spectroscopy and circular dichroism. Biochem Biophys Res Commun 1993; 191: 232–239.
Wisniewski T, Ghiso J, Frangione B. Peptides homologous to the amyloid protein of Alzheimer’s disease containing a glutamine for glutamic acid substitution have accelerated amyloid fibril formation. Biochem Biophys Res Commun 1991; 179: 1247–1254.
Hendriks L, Van Duijn CM, Cras P et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nature Genet 1992; 1: 218–221.
Mortimer JA, French LR, Hutton JT et al. Head injury as a risk factor for Alzheimer’s disease. Neurology 1985; 35: 264–267.
Mayeux R, Ottman R, Tang M-X et al. Genetic susceptibility and head injury as risk factors for Alzheimer’s disease among community-dwelling elderly persons and their first-degree relatives. Ann Neurol 1993; 33: 494–501.
Corsellis JAN, Brierley JB. Observations on the pathology of insidious dementia following head injury. J Ment Sci 1959; 105: 714–720.
Rudelli R, Strom JO, Welch PT et al. Posttraumatic premature Alzheimer’s disease: Neuropathologic findings and pathogenetic considerations. Arch Neurol 1982; 39: 570–575.
Clinton J, Ambler MW, Roberts GW. Post-traumatic Alzheimer’s disease: preponderance of a single plaque type. Neuropath Appl Neurobiol 1991; 17: 69–74.
Roberts GW, Gentleman SH, Lynch A et al. β/A4 amyloid protein deposition in the brain after head injury. Lancet 1991; 338: 1422–1423.
Nicoll JAR, Roberts GW, Graham DI. Apolipoprotein E e4 allele is associated with deposition of amyloid β-protein following head injury. Nature Medicine 1995; 1: 135–137.
Graham DI, Gentleman SM, Lynch A et al. Distribution of β-amyloid protein in the brain following severe head injury. Neuropath Appl Neurobiol 1995; 21: 27–34.
Gentleman SM, Nash MJ, Sweeting CJ et al. β-amyloid precursor protein (β-APP) as a marker for axonal injury after head injury. Neurosci Lett 1993; 160: 139–144.
Martland HS. Punch drunk. J Am Med Ass 1928; 91: 1103–1107.
Courville CB. Punch drunk. Bull Los Angeles Neurol Soc 1962; 27: 160–168.
Roberts AH. Brain damage in boxers. London, Pitman Medical Scientific Publication, 1969.
Guterman A, Smith RW. Neurological sequelae of boxing. Sports Med 1987; 4: 194–210.
Roberts GW, Whitwell HL, Acland PR et al. Dementia in a punch-drunk wife. Lancet 1990; i: 918–919.
Roberts GW, Allsop D, Bruton C. The occult aftermath of boxing. J Neurol Neurosurg Psychiatry 1990; 53: 373–378.
Tokuda T, Ikeda S, Yanagisawa N et al. Re-examination of ex-boxers’ brains using immunohistochemistry with antibodies to amyloid β-protein and tau protein. Acta Neuropathol 1991; 82: 280–285.
Roberts GW. Immunocytochemistry of neurofibrillary tangles in dementia pugilistica and Alzheimer’s disease: evidence for common genesis. Lancet 1988; ii: 1456–1458.
Wisniewski KE, Jervis GA, Moretz RC et al. Alzheimer neurofibrillary tangles in diseases other than senile and presenile dementia. Ann Neurol 1979; 7: 462–465.
Dale GE, Leigh PN, Luthert P et al. Neurofibrillary tangles in dementia pugilistica are ubiquitinated. Psychiat 1991; 54: 116–118.
Corsellis JAN, Bruton CJ, Freeman-Browne D. The aftermath of boxing. Psychol Med 1973; 3: 270–303.
Hof PR, Bouras C, Buee L et al. Differential distribution of neurofibrillary tangles in the cerebral cortex of dementia pugilistica and Alzheimer’s disease cases. Acta Neuropathol 1992; 85: 23–30.
Geddes JF, Vowles GH, Robinson SFD et al. Neurofibrillary tangles, but not Alzheimer-type pathology, in a young boxer. Neuropath Appl Neurobiol 1996; 22: 12–16.
Candy JM, McArthur FK, Oakley AE et al. Aluminum accumulation in relation to senile plaque and neurofibrillary tangle formation in the brains of patients with renal failure. J Neurol Sci 1992; 107: 210–218.
Harrington CR, Wischik CM, McArthur FK et al. Alzheimer’s disease-like changes in tau protein processing: association with aluminum accumulation in brains of renal dialysis patients. Lancet 1994; 343: 993–997.
Burks JS, Alfrey AC, Huddlestone J et al. A fatal encephalopathy in chronic haemodialysis patients. Lancet 1976; i: 764–768.
Perl DP, Brody AR. Alzheimer’s disease: x-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 1980; 208: 297–299.
Candy JM, Oakley AE, Klinowski J et al. Aluminosilicates and senile plaque formation in Alzheimer’s disease. Lancet 1986; 1: 354–357.
Chafi AH, Hauw J-J, Rancurel G et al. Absence of aluminum in Alzheimer’s disease brain tissue: electron microprobe and ion microprobe studies. Neurosci Lett 1991; 123: 61–64.
Landsberg JP, McDonald B, Watt JF. Absence of aluminum in neuritic plaque cores in Alzheimer’s disease. Nature 1992; 360: 65–68.
Masters CL, Simms G, Weinman NA et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci (USA) 1985; 82: 4245–4249.
Tabaton M, Mandybur TI, Perry G et al. The widespread alteration of neurites in Alzheimer’s disease may be unrelated to amyloid deposition. Ann Neurol 1989; 26: 771–778.
Mandybur TI, Nagpaul AS, Pappas Z et al. Alzheimer neurofibrillary change in subacute sclerosing panencephalitis. Ann Neurol 1977; 1: 103–107.
Mandybur TI. The distribution of Alzheimer’s neurofibrillary tangles and gliosis in chronic subacute sclerosing panencephalitis. Acta Neuropathol 1990; 80: 307–310.
McQuaid S, Allen IV, McMahon J et al. Association of measles virus with neurofibrillary tangles in subacute sclerosing panencephalitis: a combined in situ hybridization and immunocytochemical investigation. Neuropath Appl Neurobiol 1994; 20: 103–110.
Hirano A, Malamud N, Elizan TS et al. Amyotrophic lateral sclerosis and parkinsonism-dementia complex on Guam. Arch Neurol 1966; 2: 225–232.
Geddes JF, Hughes AJ, Lees AJ et al. Pathological overlap in cases of parkinsonism associated with neurofibrillary tangles. A study of postencephalic parkinsonism and comparison with progressive supranuclear palsy and Guamanian parkinsonismdementia complex. Brain 1993; 116: 281–302.
Buee L, Perez-Tur J, Leveugle B et al. Apolipoprotein E in Guamanian amyotrophic lateral sclerosis/parkinsonismdementia complex: genotype analysis and relationships to neuropathological changes. Acta Neuropathol 1996; (In press):.
Kiuchi A, Otsuka N, Namba Y et al. Presenile appearance of abundant neurofibrillary tangles without senile plaques in the brain in myotonic dystrophy. Acta Neuropathol 1991; 82: 1–5.
Giaccone G, Tagliavini L, Verga L et al. Neurofibrillary tangles of the Indiana kindred of Gerstmann-Straussler-Sheinker disease share antigenic determinants with those of Alzheimer’s disease. Brain Res 1990; 530: 325–329.
Namba Y, Kawatsu K, Izumi S et al. Neurofibrillary tangles and senile plaques in brain of elderly leprosy patients. Lancet 1992; 340: 978.
Cullen KM, Halliday GM. Neurofibrillary tangles in chronic alcoholics. Neuropath Appl Neurobiol 1995; 21: 312–318.
Joachim CL, Mori H, Selkoe DJ. Amyloid β-protein deposition in tissues other than brain in Alzheimer’s disease. Nature 1989; 341: 226–230.
Ikeda M, Shoji M, Yamaguchi H et al. Diagnostic significance of skin immunolabelling with antibody against native cerebral amyloid in Alzheimer’s disease. Neurosci Lett 1993; 150: 159–161.
Soininen H, Syrjanen S, Heinonen O et al. Amyloid β-protein deposition in skin of patients with dementia. Lancet 1992; 339: 245.
Tabaton M, Cammarata S, Mancardi GL et al. Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer’s disease. Neurology 1991; 41: 391–394.
Talamo BR, Rudel RA, Kosik KS et al. Pathological changes in olfactory neurons in patients with Alzheimer’s disease. Nature 1989; 337: 736–739.
Johnston JA, Cowburn RF, Norgren S et al. Increased β amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines obtained from family members with the Swedish APP670.671 mutation. FEBS Lett 1994; 354: 274–278.
Scheuner D, Eckman C, Jensen M et al. The amyloid β protein deposited in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Medicine 1996; 2: 864–870.
Bush AI, Martins RN, Rumble B et al. The amyloid precursor protein of Alzheimer’s disease is released by human platelets. J Biol Chem 1990; 265: 15977–15983.
Smith RP, Higuchi DA, Broze GJ. Platelet coagulation factor X1a-inhibitor, a form of Alzheimer’s amyloid precursor protein. Science 1990; 248: 1126–1128.
Beer J, Masters CL, Beyreuther K. Cells from peripheral tissues that exhibit high APP expression are characterized by their high membrane fusion activity. Neurodegeneration 1995; 4: 51–59.
Li JC, Kaminskas E. Deficient repair of DNA lesions in Alzheimer’s disease fibroblasts. Biochem Biophys Res Commun 1985; 129: 733–738.
Bartha E, Szelenyi J, Szilagyi K. Altered lymphocyte acetylcholinesterase activity in patients with senile dementia. Neurosci Lett 1987; 79: 190–194.
Kessler JA. Deficiency of a cholinergic differentiating factor in fibroblasts of patients with Alzheimer’s disease. Ann Neurol 1987; 21: 95–98.
Peterson C, Ratan R, Shelanski M et al. Cytosolic free calcium and cell spreading decrease in fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci (USA) 1986; 83: 7999–8001.
Ueda K, Cole G, Sundsmo M et al. Decreased adhesiveness of Alzheimer’s disease fibroblasts: Is amyloid β-protein precursor involved? Ann Neurol 1989; 25: 246–251.
Tesco G, Latorica S, Piersanti P et al. Free radical injury in skin cultured fibroblasts from Alzheimer’s disease patients. Ann NY Acad Sci 1992; 673: 149–153.
Tesco G, Vergelli M, Amaducci L et al. Growth properties of familial Alzheimer skin fibroblasts during in vitro aging. Exp Gerontol 1993; 28: 51–58.
Zubenko GS, Cohen BM, Crowdon J et al. Platelet membrane fluidity in Alzheimer’s disease. Lancet 1984; ii: 235.
Zubenko GS, Cohen BM, Reynolds CF et al. Platelet membrane fluidity in Alzheimer’s disease and major depression. Am J Psychiatry 1987; 144: 860–868.
Hicks N, Brammer MJ, Hymas N et al. Platelet membrane properties in Alzheimer’s and multi infarct dementias. Alzheimer’s Disease Assoc Disord 1987; 1: 90–97.
Piletz JE, Sarasua P, Whitehouse P et al. Intracellular membranes are more fluid in platelets of Alzheimer’s disease patients. Neurobiol Aging 1991; 12: 401–406.
Duguid JR, De La Paz R, DeGroot J. Magnetic resonance imaging of the midbrain in Parkinson’s disease. Ann Neurol 1986; 20: 744–747.
Drayer BP, Olanow CW, Burger P et al. Parkinson plus syndrome: Diagnosis using high field MR imaging of the brain. Radiology 1986; 159: 493–498.
Olanow CW. An introduction to the free radical hypothesis in Parkinson’s disease. Ann Neurol 1992; 32: 52–59.
Stern MB, Braffman BH, Skolnick BE et al. Magnetic resonance imaging in Parkinson’s disease and parkinsonian syndromes. Neurology 1989; 39: 1524–1526.
Huber SJ, Chakeres DW, Paulson GW et al. Magnetic resonance imaging in Parkinson’s disease. Arch Neurol 1990; 47: 735–737.
Earle KM. Studies in Parkinson’s disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol 1968; 27: 1–14.
Dexter DT, Wells FR, Lees AJ et al. Increased nigral iron content and alterations in other metal iron occurring in brain in Parkinson’s disease. J Neurochem 1989; 52: 1830–1836.
Sofic E, Riederer P, Heinsen H et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 1988; 74: 199–205.
Hirsch EC, Brandel JP, Galle P et al. Iron and aluminum increase in the substantia nigra of patients with Parkinson’s disease: An X-ray microanalysis. J Neurochem 1991; 56: 446–451.
Good PF, Olanow CW, Perl DP. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson’s disease: A LAMMA study. Brain Res 1992; 593: 343–346.
Morris CM, Edwardson JA. Iron histochemistry of the substantia nigra in Parkinson’s disease. Neurodegeneration 1994; 3: 277–282.
Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson’s disease and Alzheimer’s disease. Dementia 1993; 4: 61–65.
Nahmias C, Garnett ES, Firnau G et al. Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 1985; 69: 223–230.
Martin WRW, Stoessl AJ, Adam MJ et al. Positron emission tomography in Parkinson’s disease: Glucose and DOPA metabolism. Adv Neurol 1986; 45: 95–98.
Brooks DJ, Ibanez V, Sawle GV et al. Differing patterns of striatal 18F-dopa uptake in Parkinson’s disease, mutliple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547–555.
Bhatt M, Snow BJ, Martin WRW et al. Positron emission tomography suggests that the rate of progression of idiopathic parkinsonism is slow. Ann Neurol 1991; 29: 673–677.
Kuhl DE, Metter EJ, Riege WH. Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F] fluorodeoxyglucose method. Ann Neurol 1984; 15: 419–424.
Peppard RF, Martin WRW, Guttman M et al. Cerebral glucose metabolism in Parkinson’s disease and the PD complex of Guam. In: Crossman A, Sambrook M, eds. Neural Mechanisms in Disorders of Movement. London: John Libbey, 1989: 445–452.
Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol Neurosurg Psychiat 1988; 51: 745–752.
Gibb WRG, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1991; 54: 388–396.
Gibb WRG. Idiopathic Parkinson’s disease and the Lewy body disorders. Neuropath Appl Neurobiol 1986; 12: 223–234.
Fearnley JM, Lees AJ. Aging and Parkinson’s disease: Substantia nigra regional selectivity. Brain 1991; 114: 2283–2301.
Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988; 334: 345–348.
Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson’s disease. J Neuropathol Exp Neurol 1991; 50: 743–755.
Forno LS, Norville RL. Ultrastructure of Lewy bodies in the stellate ganglion. Acta Neuropathol 1978; 34: 183–197.
Gaspar P, Gray F. Dementia in idiopathic Parkinson’s disease: A neuropathological study of 32 cases. Acta Neuropathol 1984; 64: 43–52.
Jellinger K. Neuropathological substrates of Alzheimer’s disease and Parkinson’s disease. J Neurol Transm Suppl 1987; 24: 109–129.
Jellinger K. Quantitative changes in some subcortical nuclei in aging, Alzheimer’s disease and Parkinson’s disease. Neurobiol Aging 1987; 8: 556–561.
Jellinger K. Pathology of Parkinson’s disease. Changes other than the nigrostriatal pathway. Molec Chem Neuropathol 1991; 14: 153–197.
Greenfield JG, Bosanquet FD. The brain stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 1953; 16: 213–226.
Mann DMA, Yates PO. Pathological basis for neurotransmitter changes in Parkinson’s disease. Neuropath Appl Neurobiol 1983; 9: 3–19.
Whitehouse PJ, Hedreen JC, White CL et al. Basal forebrain neurons in the dementia of Parkinson’s disease. Ann Neurol 1983; 13: 243–248.
Ohama E, Ikuta F. Parkinson’s disease: Distribution of Lewy bodies and monoamine neuron system. Acta Neuropathol 1976; 34: 311.
Braak H, Braak E, Yilmazer D et al. Amygdala pathology in Parkinson’s disease. Acta Neuropathol 1994; 88: 493–500.
Braak H, Braak E, Yilmazer D de Vos RAI et al. Nigral and extranigral lesions in Parkinson’s disease. J Neural Transm 1995; 46: 15–31.
Braak H, Braak E. Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Hum Neurobiol 1986; 5: 71–82.
Matzuk MM, Saper CB. Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease. Ann Neurol 1985; 18: 552–555.
Agid Y, Ruberg M, Javoy-Agid F et al. Are dopaminergic neurons selectively vulnerable to Parkinson’s disease? Adv Neurol 1993; 60: 148–164.
Forno LS, Murphy GM, Eng LF. Immunocytochemical study of Lewy bodies in sympathetic ganglia. Neurodegeneration 1992; 1: 135–144.
Oyanagi K, Wakabayashi K, Ohama E et al. Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson’s disease. Acta Neuropathol 1990; 80: 558–559.
Wakabayashi K, Takahashi H, Ohama E et al. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 1990; 79: 581–583.
Bernheimer H, Birkmayer H, Hornykiewicz O et al. Brain dopamine and the syndromes of Parkinson and Huntington: Clinical, morphological and neurochemical correlations. J Neurol Sci 1973; 20: 415–455.
McGeer PL, Itagaki S, Akiyama H et al. Rate of cell death in Parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574–576.
German DC, Manaye KF, Smith WK et al. Mid brain dopaminergic cell loss in Parkinson’s disease: computer visualization. Ann Neurol 1989; 26: 607–614.
Halliday GM, McRitchie DA, Cartwright H et al. Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease. J Clin Neurosci 1996; 3: 1–9.
Ma SY, Collan Y, Roytta M et al. Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson’s disease and in controls. Neuropath Appl Neurobiol 1995; 21: 10–17.
Foley JM, Baxter D. On the nature of pigment granules in the cells of the locus caeruleus and substantia nigra. J Neuropathol Exp Neurol 1958; 17: 586–598.
Bazelon M, Fenichel GM, Randall J. Studies on neuromelanin. I.A melanin system in the human adult brain stem. Neurology 1969; 17: 512–519.
Mann DMA, Yates PO. Lipoprotein pigments: Their relationship to aging in the human nervous system. II-The melanin content of pigmented nerve cells. Brain 1974; 97: 489–498.
Mann DMA, Yates PO, Barton CM. Variations in melanin content with age in the human substantia nigra. Biochem Exp Biol 1977; 13: 137–139.
Mann DMA, Yates PO. The pathogenesis of Parkinson’s disease. Arch Neurol 1982; 39: 545–549.
Graham DG, Tiffany SM, Bell WR. Auto-oxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards C1300 neuroblastoma cells in vitro. Molec Pharmacol 1978; 14: 644–653.
Mann DMA, Yates PO. The effects of aging on the pigmented nerve cells of the human locus caeruleus and substantia nigra. Acta Neuropathol 1979; 47: 93–97.
McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977; 34: 33–35.
Hirai S. Aging of the substantia nigra. Adv Neurol Sci 1968; 12: 845–849.
Langston JW, Forno LS. The hypothalamus in Parkinson’s disease. Ann Neurol 1978; 3: 129–133.
Manaye KF, Mclntire DD, Mann DMA et al. Locus coeruleus cell loss in the aging human brain: a non-random process. J Comp Neurol 1995; 358: 79–87.
Marcyniuk B, Mann DMA. The topography of nerve cell loss from the locus caeruleus in elderly persons. Neurobiol Aging 1989; 10: 5–9.
Marcyniuk B, Mann DMA, Yates PO. Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down’s syndrome. J Neurol Sci 1988; 83: 15–24.
Forno LS, Alvord EC. The pathology of Parkinsonism. In: Recent Advances in Parkinson’s disease. Oxford: Blackwell Scientific Publications, 1971: 120–161.
Forno LS. Concentric hyaline intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases); relationship to Parkinsonism. J Amer Geriat Soc 1969; 17: 557–575.
Forno LS, Langston JW. Lewy bodies and aging: Relation to Alzheimer’s and Parkinson’s diseases. Neurodegeneration 1993; 2: 19–24.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Mann, D.M.A. (1997). Pathological Changes in Neurodegenerative Disease. In: Sense and Senility: The Neuropathology of the Aged Human Brain. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-6001-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-6001-2_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7749-8
Online ISBN: 978-1-4615-6001-2
eBook Packages: Springer Book Archive